In another recent, large, prospective study,27 a baseline hs-CRP level higher than 3, versus one lower than 1 mg/L, was associated with a multivariate-adjusted hazard ratio of 1.3 (95% CI, 1.0–1.6) for cancer of any type, 2.2 (95% CI, 1.0–4.6) for lung cancer, 1.9 (95% CI, 0.8–4.6) for colorectal cancer, and 0.7 (95% CI, 0.4–1.4) for breast cancer. This evidence concerns the gene CRP and colorectal cancer.